Genmab — December 2019
-
Det er helt rigtigt.
-
interestingly, InnovaTV 205 adds another arm, TV monotherapy. Adds 30 patients https://clinicaltrials.gov/ct2/history/NCT03786081?A=6&B=7&C=merged#StudyPageTop
-
Det gjorde det. Mange aktier og indeks havde det samme løft på det tidspunkt.
-
Multiple Myeloma Hub
@MM_Hub
Tomorrow is the official start of #ASH19! We want to know what content you are most looking forward to seeing from the @MM_Hub
during the meeting
https://twitter.com/MM_Hub/status/1202993896248225792 -
Vincent Rajkumar
@VincentRK
·
1 t
Ofatumumab maintenance in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study | Blood Cancer Journal #BCJhttps://www.nature.com/articles/s41408-019-0260-2 -
God morgen.
-
Janssen Announces BCMA CAR-T Therapy JNJ-4528 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Relapsed or Refractory Multiple Myeloma https://www.prnewswire.com/news-releases/janssen-announces-bcma-car-t-therapy-jnj-4528-granted-us-fda-breakthrough-therapy-designation-for-the-treatment-of-relapsed-or-refractory-multiple-myeloma-300970825.html
-
I know I'm a #latebreaker but here are my top 10 abstracts for #ASH19 (no particular order). I tried to focus on things that might affect my practice in the next 2 years. @SandyWong https://twitter.com/ninashah33/status/1203057982948495360
-
4 Questions for a Scientist Working on a Revolutionary CAR-T Therapy for Multiple Myeloma https://www.jnj.com/innovation/a-q-a-with-a-scientist-working-on-unique-car-t-therapy-for-multiple-myeloma
-
MAIA study: second interim analysis results:https://multiplemyelomahub.com/medical-information/maia-study-second-interim-analysis-results
-
Conclusion6
Patients with NDMM who are ineligible for ASCT had a 44% reduced risk of PD or death when treated with dara-Rd compared to Rd alone. Patients receiving dara-Rd had a longer PFS, higher response rate, increased the depth of response and longer duration of response compared to Rd.
Notably, in this trial, 99% of patients were aged 65 or older, and the PFS benefit was maintained regardless of age. The HR for PD or death in patients aged over 75 treated with dara-Rd was 0.63 reflecting
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind